Short-wave Diathermy in Patients With Osteoarthritis of the Hand
The Effect of Short-wave Diathermy in Patients With Osteoarthritis of the Hand: A Randomized, Double Blinded, Placebo Controlled Trial
1 other identifier
interventional
90
1 country
1
Brief Summary
Due to constant strain the joints of the hands are frequently affected by osteoarthritis (OA). Short-wave diathermy (SWD) is a form of electromagnetic therapy, which causes movement of ions, distortion of molecules, and creation of eddy currents and as a result heat is produced in deep tissue. Its claimed mechanism of action includes inducing an anti-inflammatory response, reducing joint stiffness, stimulating connective tissue repair, and reducing muscle spasm and pain. Since the available studies were performed to study the large weight-bearing joints only, there is a lack in scientific evidence for the efficacy of SWD in hand OA. The aim of this randomized, double blind, placebo-controlled study is to evaluate the effect of SWD on: joint function in patients with hand OA. joint pain in patients with hand OA. grip strength in patients with hand OA. quality of live in patients with hand OA.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Mar 2012
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2012
CompletedFirst Submitted
Initial submission to the registry
April 16, 2013
CompletedFirst Posted
Study publicly available on registry
April 24, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2016
CompletedApril 10, 2015
April 1, 2015
4.1 years
April 16, 2013
April 9, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
change in joint function in patients with hand OA (baseline, week 4 follow-up and week 12 follow-up)
week 0, week 4, week 12
Secondary Outcomes (3)
change in joint pain in patients with hand OA (baseline, week 4 follow-up and week 12 follow-up)
week 0, week 4, week 12
change in grip strength in patients with hand OA (baseline, week 4 follow-up and week 12 follow-up)
week 0, week 4, week 12
quality of live in patients with hand OA (baseline, week 4 follow-up and week 12 follow-up)
week 0, week 4, week 12
Study Arms (2)
Short-wave diathermy
ACTIVE COMPARATORShort-wave diathermy device turned on
control
PLACEBO COMPARATORShort-wave diathermy device turned off
Interventions
Device operating at a frequency of 27.12 MHz in continuous mode with an effective nominal output of 400 W in the patient circuit.
Eligibility Criteria
You may qualify if:
- Males and females \> 18 years of age. All subjects who are not surgically sterile or postmenopausal must agree and commit to the use of a reliable method of birth control for the duration of the study.
- Persistent or transient pain/aching/stiffness in at least one DIP and/or PIP joint with or without bony swelling
- Hand X-ray showing alterations typical for OA
- If NSAIDs are used to treat finger joint pain dosage must be stable for at least 4 weeks
- Able and willing to give written informed consent and to comply with the requirements of the study protocol.
You may not qualify if:
- Prior treatment with any investigational agent within 30 days, or five half lives of the product, whichever is longer.
- Patients suffering from chronic inflammatory rheumatic disease (e.g. rheumatoid arthritis or positive rheumatoid factor or positive anti-CCP antibodies, seronegative spondylarthropathy, haemochromatosis, gout, chondrocalcinosis or other auto-immune diseases
- Stable dosage for at least 3 months with chondroitin sulfate, glucosamine, biphosphonate, corticosteroids, tetracyclines and estrogens is allowed.
- Prior use of any immunomodulating drug with possible effects on pro-inflammatory cytokine metabolism within 90 days a.o. corticosteroids, methotrexate, sulfasalazine, leflunomide, d-penicillamin, anti-malarials, cytotoxic drugs, TNF blocking agents
- If the patient is of child-bearing age, he/she must use effective means of contraception during the study.
- Use of anticoagulants (cumarins or low-molecular-weight-heparins)
- Subjects with hand OA showing or having suffered from transient inflammatory attacks of the IPJs characteristic for what has been termed 'inflammatory' or 'erosive' hand OA.
- Patient who has a known blood coagulation disorder
- metall implants (such as joint endoprothesis, pace-maker, implantable cardioverter/defibrillator, stents), piercings have to be removed prior to SWD treatment
- History of cancer or lymphoproliferative disease
- Comorbidities: uncontrolled diabetes, unstable ischemic heart disease, congestive heart failure (NYHA III, IV), recent stroke (within three months), uncontrolled hypertension (defined as screening systolic blood pressure \> 160 mmHg or screening diastolic blood pressure \> 100 mmHg), severe pulmonary disease requiring hospitalization or supplemental oxygen
- Persistent or recurrent infections or severe infections requiring hospitalization or treatment with iv antibiotics within 30 days, or oral antibiotics within 14 days prior to enrollment.
- Female subjects who are breast-feeding.
- History of clinically significant drug or alcohol abuse in the last year.
- Medical history of systemic lupus erythematosus or other connective tissue disease, RA, reactive arthritis, psoriasis
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna
Vienna, Vienna, 1090, Austria
Study Officials
- PRINCIPAL INVESTIGATOR
Klaus Bobacz, MD
Medical University of Vienna
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principal investigator
Study Record Dates
First Submitted
April 16, 2013
First Posted
April 24, 2013
Study Start
March 1, 2012
Primary Completion
April 1, 2016
Study Completion
September 1, 2016
Last Updated
April 10, 2015
Record last verified: 2015-04